Medical Marijuana Use in Oncology

Wilkie, Gianna; Sakr, Bachir Joseph; Rizack, Tina

doi:10.1001/jamaoncol.2016.0155

Cited by 92 publications

(84 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the oncology setting, most data on the utility of MM in managing symptoms arise from studies in adults . Unfortunately, the quality of studies is not uniformly robust.…”

Section: Evidence For Medical Marijuana In Cancer Carementioning

confidence: 99%

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice

Ananth

Reed-Weston

Wolfe

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Medical marijuana (MM) has become increasingly legal at the state level and accessible to children with serious illness. Pediatric patients with cancer may be particularly receptive to MM, given purported benefits in managing cancer-related symptoms. In this review, we examine the evidence for MM as a supportive care agent in pediatric oncology. We describe the current legal status of MM, mechanism of action, common formulations, and potential benefits versus risks for pediatric oncology patients. We offer suggestions for how providers might approach MM requests. Throughout, we comment on avenues for future investigation on this growing trend in supportive care.

show abstract

“…In the oncology setting, most data on the utility of MM in managing symptoms arise from studies in adults . Unfortunately, the quality of studies is not uniformly robust.…”

Section: Evidence For Medical Marijuana In Cancer Carementioning

confidence: 99%

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice

Ananth

Reed-Weston

Wolfe

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Sin embargo, los estudios están limitados por el tamaño pequeño de muestra y el hecho de que todos los pacientes también recibieron su tratamiento analgésico habitual junto con un preparado de THC o un placebo. Además los pacientes señalan presentar sedación a las dosis de analgésicas de THC, lo cual puede limitar su uso 34 . Abrams, 2011, realizó un estudio en que se administró cannabis a la forma vaporizada junto con morfina de liberación sostenida u oxicodona durante cinco días, concluyendo que la administración de cannabis a la forma vaporizada aumentaba el efecto analgésico de los opioides, sin alterar significativamente sus niveles plasmáticos, lo que permitiría reducir las dosis de éstos y disminuir los efectos adversos 35 .…”

Section: Cannabis Y Dolorunclassified

“…Los resultados sugieren un beneficio como complemento a la terapia tradicional, pero se necesitan más ensayos clínicos para evaluar los efectos del cannabis y sus otros derivados 34 . El dolor neuropático supone una manifestación de un trastorno en las vías de transmisión sensorial del dolor.…”

Section: Cannabis Y Dolorunclassified

Potencial uso terapéutico de cannabis

et al. 2017

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…The attitude towards the use of cannabis is changing in many parts of the world, and approximately half of the states in the USA have approved the use of medical cannabis [13]. The Israeli Ministry of Health allows the provision of cannabis to cancer patients during therapy and up to 6 months after treatment completion, aiming to relieve chemotherapy-related AEs, even without exhausting conventional palliative modalities [14].…”

Section: Introductionmentioning

confidence: 99%

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center

et al. 2018

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed questionnaires, for all consecutive adult HL patients treated at the Tel-Aviv Medical Center between June 2010 and November 2016. One-hundred and thirty-three patients met the inclusion criteria. The median age of the cohort was 37 years, 53% were male, 46% were diagnosed at an early stage, and 88% achieved a complete response to treatment. Fifty-one patients (38%) used medical cannabis. There were no significant differences in baseline characteristics between cannabis users and nonusers. Cannabis users reported improvement in pain, general well-being, appetite, and nausea in 94, 87, 82, and 79% of cases, respectively. Importantly, 81.5% reported a high overall efficacy of cannabis in relieving symptoms. AEs related to cannabis use itself were mild. Thus, medical cannabis use is prevalent in this HL cohort, and appears to be effective in ameliorating chemotherapy-related AEs.

show abstract

Medical Marijuana Use in Oncology

Abstract: More research is needed in all areas related to the therapeutic use of marijuana in oncology.

Cited by 92 publications

References 49 publications

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice

Potencial uso terapéutico de cannabis

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center

Contact Info

Product

Resources

About